Irene M. Kang, MD, from City of Hope, shared some of the results from her analysis of cognitive impairment in women with breast cancer who participated in the RxPonder study, which assessed which patients would benefit most from chemotherapy.
Irene M. Kang, MD, a medical oncologist, the medical director of women’s health medical oncology, and an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, detailed the results from her analysis on cognitive impairment among women participating in the RxPonder study.
The study was conducted by the SWOG Cancer Research Network and sought to definitively answer the question of whether recurrence scores could be used to predict which women with hormone receptor–positive (HR+), human epidermal growth factor–negative (HER–), node-positive breast cancer would benefit from chemotherapy.
Transcript
How did cognitive impairment in women participating in the RxPonder trial change depending on participants’ menopausal status?
So, the primary difference that we found was between treatment arms. We found that patients treated with chemotherapy followed by endocrine therapy had worse cognitive function at the follow-up time points of 6 months, 12 months, and 36 months. We did see that by menopausal status, it seemed that patients on endocrine therapy had a mean cognitive function score that was worse in the short term for the premenopausal group at 6 and 12 months but returned to baseline at 36 months. In the postmenopausal group, patients treated with endocrine therapy alone had essentially stable mean cognitive function scores at the study time points.
How was cognitive impairment measured during your analysis of the RxPonder trial? What does “cognitive impairment” mean in this context?
We assessed cognitive function using a tool called the PROMIS Cognitive Abilities and Cognitive Concerns Scales. This was an 8-item questionnaire that asked participants about things like memory and focus on a 5-point Likert scale.
How can providers use the results of your analysis on patient-reported outcomes regarding cognitive impairment within the RxPonder trial when deciding whether chemotherapy would be beneficial for their patients with HR+, HER–, node-positive breast cancer?
So, our analysis showed that cognitive impairment is experienced at a higher rate with chemo-endocrine therapy rather than endocrine therapy alone, and shows that in some patients, these symptoms persist even out to 36 months. I think these data highlight that using something like a molecular risk assay to avoid chemotherapy in patients who would otherwise not benefit is really important in preventing such a debilitating symptom.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
2 Commerce Drive
Cranbury, NJ 08512